Authors: Stefania Rany Seran*1, Didik Hasmono2, Suharjono2
Department of Pharmaceutics, Faculty of Pharmacy,Airlangga University
60286, Surabaya, Indonesia
*E-mail : alexacutez01@gmail.com
Abstract
Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized by a progressive decline in lung function, is considered to be a leading cause of morbidity and mortality. Long-acting inhaled bronchodilators, such as long-acting β2 agonists (LABAs) or long-acting muscarinic antagonists (LAMAs), are the cornerstone of maintenance therapy for patients with moderate-to-very-severe COPD.Tiotropium, a once-daily dosing LAMA, demonstrated sustained improvements in lung function as well as improved health-related quality of life, reduced exacerbations, and increased survival without altering the rate of decline in the mean forced expiratory volume in 1 second (FEV1) with fairly tolerable side effects. Olodaterol is a once-daily dosing LABA that has proven to be effective in improving lung function, reducing rescue medication use, and improving dyspnea and health-related quality of life, as well as improving exercise endurance with an acceptable safety profile. The combination of olodaterol and tiotropium provided additional improvements in lung function greater than monotherapy with each drug alone.
Keywords: chronic obstructive pulmonary disease, bronchodilators, long-acting β2 agonists, long-acting muscarinic antagonist, olodaterol, tiotropium
